Soligenix Reports $9 Million in Cash and Warns of Substantial Doubt About Its Continued Operations
Key Facts
Soligenix reported results on November 6 for the quarter ended September 30, 2026, saying it had approximately $9.0 million in cash and cash equivalents, which it expects to fund its current operating plan through the second quarter of 2028. In its accompanying filing with the U.S. Securities and Exchange Commission, the company said substantial doubt about its ability to continue as a going concern remains. It linked that doubt to its ongoing evaluation of strategic alternatives without completing a transaction or obtaining additional assets for its programs. The warning puts the cash runway estimate in the context of the need for financing or assets to continue developing its drug pipeline. The company’s shares closed at $0.335 in the November 6 session.
The operating figures show continued cash burn during the period. The company reported a net loss of $5,929,844 and used $5,488,423 in cash in operating activities during the nine months ended September 30, 2026. In the third quarter alone, it recorded no revenue, as it also did in the year-earlier period. The quarterly loss was $1.1 million, or $0.05 per share, compared with a loss of $2.5 million, or $0.58 per share, a year earlier. The company attributed the narrower loss mainly to lower research and development expenses related to the completion of the FLASH2 trial and HyBryte development activities, as well as a gain from the extinguishment of vendor liabilities.
Research and development expenses fell to $0.4 million in the third quarter from $1.6 million in the same quarter of 2025. The company said the decline reflected lower costs following the completion of the FLASH2 trial and HyBryte development activities. The interim data monitoring committee completed its interim efficacy analysis of the FLASH2 trial in April 2026 and recommended stopping it for futility. After reviewing the recommendation, the board decided in June to terminate the HyBryte program, and the company began an orderly shutdown of the trial and related activities. Shutdown costs totaled approximately $62,000 through September 30, and the company said the process was substantially complete as of the filing date.
Meanwhile, the company provided an update on SGX945, known as dusquetide, for Behçet’s disease. The chief executive said the drug showed encouraging signs of biological activity and was generally safe and well tolerated in a small, open-label Phase 2a proof-of-concept study. These results remain tied to a limited early-stage study, while the filing described the company’s ability to continue operations as dependent on developing its remaining pipeline assets, including dusquetide, or finding new drug candidates, as well as securing financing. The company warned that it could reduce or cease operations if it is unable to do so. The filing thus reflects the different status of the two programs: development of HyBryte has stopped, while work continues on other pipeline assets.
Soligenix said it is evaluating partnerships, licensing, mergers and acquisitions, grants and government contracts while continuing to develop its existing pipeline. Its filing said capital-raising options include public or private equity offerings, strategic transactions, product alliances and collaborations, as well as grants, government contracts and share sales through an ATM facility. As of September 30, 2026, gross share sales under the Rodman ATM agreement totaled approximately $6,901,000, while the company received approximately $6,682,000 after commissions and fees and before other offering costs. The company had reported on June 30 that it held $9,811,141 in cash and cash equivalents and had working capital of $6,499,947. It had also received a Nasdaq notice of noncompliance with the $1.00 minimum bid price requirement for continued listing, according to a June 10, 2026 notice.